IL2 and neoplasm: Specifically, administration of 2M3B1PP and IL-2 preceding Vδ2-enriched autologous PBMC adoptive cell therapy, with low-dose IL-2 and/or zoledronate as adjunct(s), facilitated prolongation of tumor doubling time [12, 192, 193].